Disclosures: Wajiha Khan: Nothing to Disclose, David Kim: Nothing to Disclose, Ariana Shari: Nothing to Disclose, Hamza Khan: Nothing to Disclose, Alexander Le: Nothing to Disclose, Christopher Hawryluk: Nothing to Disclose, Ivan Bobkov: Nothing to Disclose, Ahmed Al-Khazraji: Nothing to Disclose, Kaveh Hajifathalian: Nothing to Disclose 1083 IMPROVED LIVER FIBROSIS REGRESSION AFTER DIRECT-ACTING ANTIVIRAL THERAPY IN HEPATITIS C PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Alexis McCary 1 Yi-shin Sheu 1 Karen Chesbrough 1 Cabell Jonas 1 , 1 Mid-Atlantic Permanente Medical Group Background: One third of the US population has some degree of liver steatosis, and many patients with Chronic Hepatitis C (CHC) meet criteria for metabolic dysfunction-associated steatotic liver disease (MASLD)
Biochemistry 37:1792317930 van Dalen CJ, Whitehouse MW, Winterbourn CC, Kettle AJ (1997) Thiocyanate and chloride as competing substrates for myeloperoxidase
Hepatology 60 FisherC
As shown in Figure 9, most of the SlUGT genes, except for SlUGT23 , SlUGT48 , SlUGT72 , and SlUGT113 , could be expressed in tissue sites